Targeting DTX2 decreased the related histone epigenetic modifications of CXCL2 and CXCL6, thereby attenuating the immunosuppressive characteristics of the TME and sensitizing HCC cells to anti‐PD1 immunotherapy. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.